Hunting for the Off-Target Properties of Ticagrelor on Endothelial Function in Humans (HI-TECH)
- Conditions
- Cardiovascular Diseases
- Interventions
- Registration Number
- NCT02587260
- Lead Sponsor
- Erasmus Medical Center
- Brief Summary
The purpose of this randomized, cross-over study, is to ascertain if ticagrelor, but not prasugrel or clopidogrel, is associated to an improved endothelial function as assessed with peripheral arterial tonometry and markers of endothelial function measurement in post-ACS patients.
- Detailed Description
Extensive literature documents that endothelial dysfunction is associated with almost every condition predisposing to atherosclerosis and cardiovascular disease. Hence, endothelial dysfunction is significantly associated with the burden of cardiovascular risk and can be considered a barometer of the total risk burden. Importantly, microvascular dysfunction has been shown to increase risk of future cardiovascular events.
This study aims to clarify if ticagrelor, but not prasugrel or clopidogrel is associated to an improved reactive hyperemia index (RHI) and circulating levels of specific biomarkers of endothelial function, at treatment steady state. Ticagrelor has previously been demonstrated to increase adenosine levels by inhibiting adenosine reuptake in red blood cells, by inhibiting the equilibrative nucleoside transporter (ENT)-1. Furthermore, ticagrelor can induce adenosine triphosphate (ATP) release from human red blood cells. Interestingly, ticagrelor, but not clopidogrel or prasugrel have been recently shown to be associated to an improved endothelial function as evaluated with peripheral arterial tonometry after forearm ischemia.
Post-ACS patients (who experienced an acute coronary syndrome and thereby started therapy with an oral P2Y12 inhibitor at least 30 days before) will be consecutively screened for possible inclusion. Patients will then be randomised to receive in a sequential manner the three oral P2Y12 blockers (i.e.) ticagrelor, prasugrel or clopidogrel for at least 30 days each, according to a balanced cross-over study design including the sequences below:
Seq\\ Per P.I P.II P.III S.I T P C S.II T C P S.III P T C S.IV P C T S.V C T P S.VI C P T During the three months study period the therapy with the P2Y12 inhibitor will be switched as for randomization sequence scheme.
When started, each drug will be given with the corresponding loading dose of 600 mg for clopidogrel and then continued at 75 mg/day, 180 mg for ticagrelor and then continued at 90 mg b.i.d. and 60 mg for prasugrel and then continued at 10 mg/day (5 mg/day for patients ≥75 years or weighing ≤ 60 kg).
The main measurements, including reactive hypermedia index, PRU, aspirin reaction units, and circulating markers of endothelial function will be performed at baseline, after P2Y12-inhibitor loading dose, before and after P2Y12-inhibitor maintenance dose.
During the visit, blood pressure will be measured in the contralateral arm before examination. The EndoPAT probes will be placed on the index fingers. If the index finger will be missing or deformed, another finger will be used, using the same finger on both hands. Baseline registration will be conducted for 5 min. The test arm will be then occluded for 5 min, using a standard blood pressure cuff placed on the upper arm. Subsequently, the cuff was deflated and the registration continued for 5 more minutes. After EndoPAT, blood will be drawn to collect serum and plasma for biomarkers assessment \[Asymmetrical dimethylarginine (ADMA), adenosine plasma concentration, von willebrand factor antigen, endothelin-1, C-reactive protein, soluble fms-like tyrosine kinase-1 (sFLT-1), intercellular cell adhesion molecule-1 (ICAM-1), vascular cell adhesion molecule-1 (VCAM-1), prothrombin fragment 1+2, fibrinopeptide A, and thrombin-antithrombin complex (TAT)\]. To assess the relationship between residual platelet reactivity or percent inhibition and effect of P2Y12 oral blocker on endothelial function, platelet function testing will be also carried out acutely and at treatment steady state by means of the Verifynow system using both P2Y12 and aspirin assays.
Based on previous findings, we set mean RHI at 1.8 with a within subjects SD of 0.31. Hence, 36 patients completing all sequences (i.e. 6 pt/sequence) will provide 90% power to detect a 10% RHI relative change in the ticagrelor group with a two-sided alpha level at 5%. To account for drop outs as well as incomplete data assessment at all time points, a final sample size of 50 patients will be recruited.
Patients will be provided with a regular drug prescription (standard of care medication). At each follow-up the investigator will collect information about adherence to the study drug and register the charge number of the prescribed P2Y12.
Allocation of study treatment will be performed via a web-based interactive randomization system, based on a computer-generated random sequence with a random block size stratified according to the type of P2Y12 inhibitor (ticagrelor vs prasugrel vs clopidogrel) as well as for the presence of diabetes mellitus.
Adverse events are defined as any undesirable experience occurring to a subject during the study, whether or not considered related to study. All adverse events reported spontaneously by the subject or observed by the investigator or his staff will be recorded. Serious adverse events in this study are considered to be extremely rare.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 54
- Patients older than 18 years.
- Patients who experienced an Acute Coronary Syndrome (including STEMI or NSTEMI) at least 30 days before.
- Patients on ongoing treatment for at least 30 days with dual anti-platelet therapy consisting of aspirin, at doses of 75-160 mg daily and one commercially available P2Y12 oral inhibitor , including ticagrelor, clopidogrel or prasugrel.
- Patients who remained free from bleeding (defined as BARC type 2 or greater) or ischemic recurrences.
- Signed informed consent All inclusion criteria are required.
- Administration of fibrinolytics or glycoprotein IIb/IIIa inhibitors in the previous 30 days.
- Major surgery within 30 days or any planned surgical or percutaneous intervention.
- Active bleeding or previous clinical relevant bleeding or stroke in the last 6 months.
- Previous transient ischemic attack or intracranial bleeding.
- Thrombocytopenia.
- Oral anticoagulant therapy.
- Vasculitis or any know immunological disorder.
- Severe hepatic failure.
- Uncontrolled hypertension (systolic or diastolic arterial pressure >180 mmHg or 120, respectively, despite medical therapy).
- Known intolerance to aspirin or to clopidogrel or prasugrel or ticagrelor.
- Limited life expectancy, e.g. neoplasms, others.
- Inability to obtain informed consent.
- Pregnancy.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- CROSSOVER
- Arm && Interventions
Group Intervention Description Sequence I Ticagrelor Ticagrelor in the period I Prasugrel in the period II Clopidogrel in the period III Sequence I Prasugrel Ticagrelor in the period I Prasugrel in the period II Clopidogrel in the period III Sequence I Clopidogrel Ticagrelor in the period I Prasugrel in the period II Clopidogrel in the period III Sequence III Ticagrelor Prasugrel in the period I Ticagrelor in the period II Clopidogrel in the period III Sequence II Ticagrelor Ticagrelor in the period I Clopidogrel in the period II Prasugrel in the period III Sequence II Prasugrel Ticagrelor in the period I Clopidogrel in the period II Prasugrel in the period III Sequence II Clopidogrel Ticagrelor in the period I Clopidogrel in the period II Prasugrel in the period III Sequence III Clopidogrel Prasugrel in the period I Ticagrelor in the period II Clopidogrel in the period III Sequence III Prasugrel Prasugrel in the period I Ticagrelor in the period II Clopidogrel in the period III Sequence IV Ticagrelor Prasugrel in the period I Clopidogrel in the period II Ticagrelor in the period III Sequence IV Clopidogrel Prasugrel in the period I Clopidogrel in the period II Ticagrelor in the period III Sequence IV Prasugrel Prasugrel in the period I Clopidogrel in the period II Ticagrelor in the period III Sequence V Ticagrelor Clopidogrel in the period I Ticagrelor in the period II Prasugrel in the period III Sequence V Prasugrel Clopidogrel in the period I Ticagrelor in the period II Prasugrel in the period III Sequence VI Ticagrelor Clopidogrel in the period I Prasugrel in the period II Ticagrelor in the period III Sequence V Clopidogrel Clopidogrel in the period I Ticagrelor in the period II Prasugrel in the period III Sequence VI Clopidogrel Clopidogrel in the period I Prasugrel in the period II Ticagrelor in the period III Sequence VI Prasugrel Clopidogrel in the period I Prasugrel in the period II Ticagrelor in the period III
- Primary Outcome Measures
Name Time Method Improvement of endothelial function at steady state After 30 days of therapy with assigned P2Y12-inhibitor Evaluation if ticagrelor, at steady state (i.e. after 30 day therapy), will be associated to an improved endothelial function as compared to clopidogrel or prasugrel when assessed with endopath system 1-2 hour(s) after maintenance drug intake.
- Secondary Outcome Measures
Name Time Method Improvement of endothelial function, both acutely and at steady state One or 2 hour(s) after P2Y12-inhibitor loading dose administration and before and 1 or 2 hour(s) after maintenance dose administration To assess if treatment with ticagrelor, both acutely and at steady state is associated to an improved endothelial function phenotype as compared to clopidogrel or prasugrel. The assessment is made with measurement of blood markers of endothelial function.
Trial Locations
- Locations (5)
Inselspitäl University Medical Center
🇨🇭Bern, Switzerland
Erasmus MC
🇳🇱Rotterdam, Netherlands
Policlinico San Matteo
🇮🇹Pavia, Italy
VU Medical Center
🇳🇱Amsterdam, Netherlands
Hospital Clinic
🇪🇸Barcelona, Spain